KATHMANDU, April 13: Aero Pharmaceuticals Limited is set to issue its Initial Public Offering (IPO), with Global IME Capital Limited appointed as the issue and sales manager. A total of 1.5 million shares, each with a face value of Rs 100, will be offered to the general public.
An agreement to this effect was signed on Thursday between Aero Pharmaceuticals and Global IME Capital. The deal was signed by Uddhav Prasad Mainali, chairperson of Aero Pharmaceuticals’ Board of Directors, and Mandeep Luitel, chief executive officer of Global IME Capital.
Aero Pharmaceuticals has an authorized capital of Rs 1 billion and a paid-up capital of Rs 750 million. Its corporate office is located in Basundhara of Kathmandu Metropolitan City-3, while its manufacturing facility is situated in Sudal, Bhaktapur.
Aero Bricks starts production of blocks
The company is backed by a group of prominent investors with experience in various sectors, including well-known entrepreneurs and industrialists. Established in fiscal year 2014/15 as a private company, it was later converted into a public limited company in FY 2023/24.
Over the past five years, the company has been manufacturing and selling a range of medicines, including tablets, capsules, ointments, external liquids, dry suspensions, and powders. It currently markets 107 pharmaceutical brands, specializing in high-quality antibiotics and medications used for hypertension and diabetes.
In the current fiscal year, Aero Pharmaceuticals has also started producing veterinary medicines as part of its market expansion strategy. The company claims a significant share of the domestic pharmaceutical market.
To support its plans to export to international markets shortly, the company has obtained the WHO-GMP certification, aligning with global standards set by the World Health Organization.
